TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE
6.1. Overview
6.2. Consumables
6.3. Equipment
6.4. Software Solutions
7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE
7.1. Overview
7.2. Commercial Stage Manufacturing
7.3. Research Stage Manufacturing
8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION
8.1. Overview
8.2. Upstream Processing
8.3. Harvesting
8.4. Downstream Processing
9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER
9.1. Overview
9.2. Life Science Companies
9.3. Contract Research Organizations
9.4. Contract Manufacturing Organizations
9.5. Cell Banks
10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Cell and Gene Therapy Biomanufacturing Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Cell and Gene Therapy Biomanufacturing Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2023
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Lonza Group
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Thermo Fisher Scientific Inc.
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Merck KGaA
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. WuXi AppTec
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Catalent, Inc.
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Samsung Biologics
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. FUJIFILM Diosynth Biotechnologies
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. CHARLES RIVER LABORATORIES
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Cytiva
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. NOVASEP
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 11 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 12 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 13 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 15 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 16 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 17 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 19 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 20 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 21 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 22 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 23 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 24 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 25 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 26 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 27 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 28 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 29 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 30 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 31 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 32 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 33 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 34 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 35 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 36 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 37 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 38 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 39 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 40 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 41 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 42 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 43 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 44 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 45 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 46 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 47 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 48 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 49 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 50 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 51 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 52 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 53 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 54 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 55 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 56 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 57 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 58 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 59 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 60 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 61 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 62 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 63 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 64 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 65 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 66 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 67 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 68 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 69 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 70 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 73 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 74 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 75 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 76 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 77 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 78 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 79 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 80 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 81 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 82 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 83 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 84 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 85 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 86 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 87 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 88 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
TABLE 89 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 90 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
FIGURE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY PRODUCT TYPE, 2023
FIGURE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY USAGE, 2023
FIGURE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY APPLICATION, 2023
FIGURE 7 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY END USER, 2023
FIGURE 8 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 LONZA GROUP: SWOT ANALYSIS
FIGURE 16 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 18 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 MERCK KGAA: SWOT ANALYSIS
FIGURE 20 WUXI APPTEC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 WUXI APPTEC: SWOT ANALYSIS
FIGURE 22 CATALENT, INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 CATALENT, INC..: SWOT ANALYSIS
FIGURE 24 SAMSUNG BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 SAMSUNG BIOLOGICS: SWOT ANALYSIS
FIGURE 26 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: SWOT ANALYSIS
FIGURE 28 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 30 CYTIVA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 CYTIVA: SWOT ANALYSIS
FIGURE 32 NOVASEP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 NOVASEP: SWOT ANALYSIS
